MCID: ALK015
MIFTS: 40

Alk-Positive Anaplastic Large Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Positive Anaplastic Large Cell Lymphoma:

Name: Alk-Positive Anaplastic Large Cell Lymphoma 60
Anaplastic Large Cell Lymphoma, Alk Negative 74
Anaplastic Large Cell Lymphoma, Alk-Positive 74
Alk+ Anaplastic Large Cell Lymphoma 60
Alk+ Alcl 60

Characteristics:

Orphanet epidemiological data:

60
alk-positive anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:



External Ids:

ICD10 via Orphanet 35 C84.6
Orphanet 60 ORPHA300895

Summaries for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Positive Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk negative, is related to alk-negative anaplastic large cell lymphoma and anaplastic large cell lymphoma. An important gene associated with Alk-Positive Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Glioma. The drugs Vincristine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and breast.

Related Diseases for Alk-Positive Anaplastic Large Cell Lymphoma

Diseases in the Alk-Positive Anaplastic Large Cell Lymphoma family:

Alk-Negative Anaplastic Large Cell Lymphoma

Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 alk-negative anaplastic large cell lymphoma 30.4 ALK STAT3
2 anaplastic large cell lymphoma 30.0 ALK JAK3 MCL1 MUC1 NPM1 STAT3
3 lung cancer susceptibility 3 29.7 ALK MUC1 STAT3
4 lymphoma 11.2
5 hemophagocytic lymphohistiocytosis 10.3
6 leukemia 10.3
7 leukemia, chronic lymphocytic 2 10.2
8 breast cancer 10.2
9 leukemia, chronic lymphocytic 10.2
10 neurofibromatosis, type i 10.2
11 neurofibromatosis, type iv, of riccardi 10.2
12 janus kinase-3 deficiency 10.2
13 lymphocytic leukemia 10.2
14 lipoid nephrosis 10.2
15 adenocarcinoma 10.2
16 inflammatory breast carcinoma 10.2
17 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.2
18 myeloid leukemia 10.2
19 leukemia, b-cell, chronic 10.2
20 tetraploidy 10.2
21 hypoxia 10.2
22 intravascular large b-cell lymphoma 10.2
23 lymphomatoid papulosis 10.2 ALK NPM1
24 peripheral t-cell lymphoma 10.1
25 lymphatic system cancer 10.1 ALK NPM1
26 lymphoma, hodgkin, classic 10.1
27 asthma 10.1
28 hematopoietic stem cell transplantation 10.1
29 pemphigus foliaceus 10.1
30 lymphoproliferative syndrome 10.1
31 sarcoma 10.1
32 capillary leak syndrome 10.1
33 syphilis 10.1
34 cytokine deficiency 10.1
35 soft tissue sarcoma 10.1
36 systemic capillary leak syndrome 10.1
37 inflammatory myofibroblastic tumor 10.0 ALK NPM1
38 perineurioma 9.9 ALK MUC1
39 eccrine porocarcinoma 9.9 MUC1 STAT3
40 intraneural perineurioma 9.9 ALK MUC1
41 mucinous adenocarcinoma 9.9 ALK MUC1
42 ethmoid sinusitis 9.8 MUC1 TWIST1
43 myeloproliferative neoplasm 9.8 JAK3 STAT3
44 pneumothorax 9.8 ALK MUC1
45 respiratory system cancer 9.8 ALK STAT3
46 hematologic cancer 9.8 ALK MCL1 NPM1
47 lymphoma, non-hodgkin, familial 9.8 ALK MCL1 NPM1
48 primary cutaneous anaplastic large cell lymphoma 9.7 ALK MUC1 NPM1
49 reticulosarcoma 9.7 ALK MUC1 NPM1
50 leukemia, acute myeloid 9.6 MCL1 NPM1 STAT3

Graphical network of the top 20 diseases related to Alk-Positive Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Positive Anaplastic Large Cell Lymphoma

Drugs & Therapeutics for Alk-Positive Anaplastic Large Cell Lymphoma

Drugs for Alk-Positive Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
2
Ifosfamide Approved Phase 4 3778-73-2 3690
3
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 53-03-2 5865
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Cisplatin Approved Phase 4,Phase 2 15663-27-1 2767 441203 84093
7
Etoposide Approved Phase 4,Phase 2,Phase 1 33419-42-0 36462
8
Gemcitabine Approved Phase 4,Phase 2 95058-81-4 60750
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
11
Doxorubicin Approved, Investigational Phase 4,Phase 1,Phase 2 23214-92-8 31703
12
Crizotinib Approved Phase 4 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
13
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
14
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
15
leucovorin Approved Phase 4 58-05-9 143 6006
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
17
Doxil Approved June 1999 Phase 4,Phase 1,Phase 2 31703
18
Pirarubicin Investigational Phase 4 72496-41-4
19
Isophosphamide mustard Phase 4 0
20 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2
21 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
22 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 1
23 Etoposide phosphate Phase 4,Phase 2,Phase 1
24 Hormones Phase 4,Phase 1,Phase 2
25 BB 1101 Phase 4
26 Immunosuppressive Agents Phase 4,Phase 1,Phase 2
27 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Phase 2
28 Hormone Antagonists Phase 4,Phase 1,Phase 2
29 Immunologic Factors Phase 4,Phase 1,Phase 2
30 Topoisomerase Inhibitors Phase 4,Phase 1,Phase 2
31 Alkylating Agents Phase 4,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
33 Antimitotic Agents Phase 4,Phase 1,Phase 2
34 Antineoplastic Agents, Phytogenic Phase 4,Phase 1,Phase 2
35 Antirheumatic Agents Phase 4,Phase 2,Phase 1
36 glucocorticoids Phase 4,Phase 1,Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1,Phase 2
38 Protein Kinase Inhibitors Phase 4,Phase 1,Phase 2
39 Dermatologic Agents Phase 4,Phase 2,Phase 1
40 Antimetabolites Phase 4,Phase 2
41 Vitamin B Complex Phase 4
42 Nucleic Acid Synthesis Inhibitors Phase 4
43 Antimetabolites, Antineoplastic Phase 4,Phase 2
44 Folate Phase 4
45 Vitamin B9 Phase 4
46 Folic Acid Antagonists Phase 4
47
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
48
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 5284616 6436030
49
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2,Phase 2 83-43-2 6741
50
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2,Phase 2 2921-57-5

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
3 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
4 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
5 Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT02729961 Phase 1, Phase 2 Brentuximab Vedotin;Ceritinib
6 Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT03719898 Phase 2 Brigatinib
7 A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms Recruiting NCT03493451 Phase 2 BGB A317
8 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Etoposide;Prednisone
9 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
10 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Active, not recruiting NCT00069238 Phase 2 EPOCH
11 CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study Active, not recruiting NCT01719835 Phase 2 Cyclophosphamide;Gemcitabine;Doxorubicin;Vincristine;Prednisolone;methylprednisolone;Cisplatin
12 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
13 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Recruiting NCT03905135 Phase 1 rhIL-15
14 Risk Stratification of Nodal PTCL Active, not recruiting NCT03040206

Search NIH Clinical Center for Alk-Positive Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Positive Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Positive Anaplastic Large Cell Lymphoma:

42
T Cells, Bone, Breast, Myeloid, B Cells, Nk Cells, Bone Marrow

Publications for Alk-Positive Anaplastic Large Cell Lymphoma

Articles related to Alk-Positive Anaplastic Large Cell Lymphoma:

(show top 50) (show all 113)
# Title Authors Year
1
CD38 is not expressed in pediatric ALK-positive anaplastic large cell lymphoma. ( 30408331 )
2019
2
Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. ( 30679328 )
2019
3
Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. ( 30742941 )
2019
4
Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib. ( 30819904 )
2019
5
ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. ( 31004022 )
2019
6
Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma. ( 31052302 )
2019
7
Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma. ( 28665006 )
2018
8
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. ( 29030834 )
2018
9
CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. ( 29512859 )
2018
10
Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma. ( 29609590 )
2018
11
Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib. ( 29622884 )
2018
12
Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma. ( 29642597 )
2018
13
Small cell variant of ALK-positive anaplastic large cell lymphoma with primary subcutaneous presentation: A case report. ( 29952979 )
2018
14
ALK-positive anaplastic large-cell lymphoma with primary bone involvement: A rare case and review of the literature. ( 30173234 )
2018
15
Fine-needle aspiration cytology yield as a basis for morphological, molecular, and cytogenetic diagnosis in alk-positive anaplastic large cell lymphoma with atypical clinical presentation. ( 27468968 )
2017
16
Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. ( 27795556 )
2017
17
ALK-positive anaplastic large cell lymphoma undiagnosed in a patient with tuberculosis: a case report and review of the literature. ( 28490385 )
2017
18
Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. ( 28878445 )
2017
19
Minimal Change Disease as Initial Presentation of ALK-Positive Anaplastic Large-Cell Lymphoma in a Pediatric Patient. ( 29279700 )
2017
20
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman [Retraction]. ( 29296088 )
2017
21
Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. ( 26133723 )
2016
22
Intra-abdominal ALK-positive anaplastic large cell lymphoma in a patient with neurofibromatosis type 1. ( 26272700 )
2016
23
Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. ( 26734914 )
2016
24
ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy. ( 26834485 )
2016
25
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman. ( 27445489 )
2016
26
ALK-positive anaplastic large-cell lymphoma with marked leukemoid reaction and hemophagocytic lymphohistiocytosis. ( 27563714 )
2016
27
ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine. ( 27761194 )
2016
28
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. ( 27793034 )
2016
29
A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. ( 27821172 )
2016
30
Primary central nervous system ALK-positive anaplastic large cell lymphoma in an adult: A rare case report. ( 27930548 )
2016
31
Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma. ( 27498729 )
2016
32
ALK-positive anaplastic large cell lymphoma with prominent bone involvement. ( 26018037 )
2015
33
ALK-positive anaplastic large cell lymphoma presenting with hemophagocytic lymphohistiocytosis. ( 26114236 )
2015
34
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. ( 26338968 )
2015
35
Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 26420623 )
2015
36
Endobronchial ALK-Positive Anaplastic Large Cell Lymphoma Presenting Massive Hemoptysis. ( 26508931 )
2015
37
ALK Positive Anaplastic Large Cell Lymphoma With Pure Leptomeningeal Involvement: Unique Case Report and Review of the Literature. ( 24407988 )
2015
38
Editor in Chief: Response to Eyre et al. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease". ( 24953081 )
2015
39
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 25421750 )
2015
40
ALK Positive Anaplastic Large Cell Lymphoma Presenting as Extensive Bone Involvement. ( 25738071 )
2015
41
The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines. ( 25797883 )
2015
42
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. ( 25921060 )
2015
43
Metachronous classical Hodgkin's lymphoma and ALK-positive anaplastic large cell lymphoma. ( 25938345 )
2015
44
MicroRNA and ALK-positive anaplastic large cell lymphoma. ( 25961697 )
2015
45
ALK-positive anaplastic large cell lymphoma: an evolving story. ( 25961700 )
2015
46
Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant. ( 25971833 )
2014
47
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. ( 23975180 )
2014
48
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24297868 )
2014
49
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24509625 )
2014
50
Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease free survival in an old adult. ( 24696735 )
2014

Variations for Alk-Positive Anaplastic Large Cell Lymphoma

Expression for Alk-Positive Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Positive Anaplastic Large Cell Lymphoma.

Pathways for Alk-Positive Anaplastic Large Cell Lymphoma

Pathways related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.46 JAK3 MCL1 MUC1 STAT3 TWIST1
2
Show member pathways
12.27 ALK JAK3 STAT3
3
Show member pathways
12.25 JAK3 MCL1 STAT3
4
Show member pathways
12.15 JAK3 MCL1 STAT3
5
Show member pathways
11.8 JAK3 MCL1 STAT3
6 11.27 MCL1 NPM1
7 11.09 STAT3 TWIST1
8 11.08 JAK3 MCL1 MUC1 STAT3 TWIST1
9
Show member pathways
11.03 JAK3 STAT3
10
Show member pathways
10.94 JAK3 STAT3
11 10.76 JAK3 STAT3

GO Terms for Alk-Positive Anaplastic Large Cell Lymphoma

Biological processes related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to cytokine GO:0034097 9.43 MCL1 STAT3
2 interleukin-7-mediated signaling pathway GO:0038111 9.4 JAK3 STAT3
3 interleukin-15-mediated signaling pathway GO:0035723 9.37 JAK3 STAT3
4 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.32 JAK3 STAT3
5 interleukin-9-mediated signaling pathway GO:0038113 9.26 JAK3 STAT3
6 negative regulation of apoptotic process GO:0043066 9.26 MCL1 NPM1 STAT3 TWIST1
7 interleukin-21-mediated signaling pathway GO:0038114 9.16 JAK3 STAT3
8 cytokine-mediated signaling pathway GO:0019221 9.02 JAK3 MCL1 MUC1 STAT3 TWIST1

Molecular functions related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.16 JAK3 STAT3
2 transcription factor binding GO:0008134 9.13 NPM1 STAT3 TWIST1
3 protein homodimerization activity GO:0042803 8.92 MCL1 NPM1 STAT3 TWIST1

Sources for Alk-Positive Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....